1. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients
- Author
-
Kostareli, Efterpi, Hielscher, Thomas, Zucknick, Manuela, Baboci, Lorena, Wichmann, Gunnar, Holzinger, Dana, Mücke, Oliver, Pawlita, Michael, Del Mistro, Annarosa, Boscolo Rizzo, Paolo, Da Mosto, Maria Cristina, Tirelli, GIAN CARLO, Plinkert, Peter, Dietz, Andreas, Plass, Christoph, Weichenhan, Dieter, Hess, Jochen, BOSCOLO RIZZO, Paolo, Kostareli, Efterpi, Hielscher, Thoma, Zucknick, Manuela, Baboci, Lorena, Wichmann, Gunnar, Holzinger, Dana, Mücke, Oliver, Pawlita, Michael, Del Mistro, Annarosa, Boscolo Rizzo, Paolo, Da Mosto, Maria Cristina, Tirelli, GIAN CARLO, Plinkert, Peter, Dietz, Andrea, Plass, Christoph, Weichenhan, Dieter, Hess, Jochen, and BOSCOLO RIZZO, Paolo
- Subjects
Male ,0301 basic medicine ,Oncology ,squamous cell carcinoma ,medicine.medical_specialty ,Cancer Research ,HPV ,DNA methylation ,head and neck cancer ,HNSCC ,MassARRAY ,OPSCC ,Molecular Biology ,Kaplan-Meier Estimate ,Biology ,Epigenesis, Genetic ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Promoter Regions, Genetic ,Proportional Hazards Models ,Human papillomavirus 16 ,Squamous Cell Carcinoma of Head and Neck ,Proportional hazards model ,Head and neck cancer ,Methylation ,Middle Aged ,Prognosis ,medicine.disease ,Head and neck squamous-cell carcinoma ,Clinical trial ,030104 developmental biology ,CpG site ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Cohort ,Immunology ,Carcinoma, Squamous Cell ,CpG Islands ,Female ,Research Paper - Abstract
Project was completed in previous post, I joined DMU on 01/01/2016 Infection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9%) and a low prevalence of HPV16-related tumors (8.8%) was analyzed by MassARRAY to determine a previously established prognostic methylation score (MS). Kaplan-Meier revealed a highly significant correlation between a high MS and a favorable survival for OPSCC (P = 0.0004) and for non-OPSCC (P
- Published
- 2016
- Full Text
- View/download PDF